Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06468956

Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis

Moderate to Severe Atopic Dermatitis Clinical Trial

Official title:
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of SHR-1819 Injection in Patients With Moderate to Severe Atopic Dermatitis

Clinical Trial Summary

This trial was designed to evaluate the efficacy and safety of SHR-1819 injection in patients with atopic dermatitis.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06468956
Study type Interventional
Source Guangdong Hengrui Pharmaceutical Co., Ltd
Contact Xiaoyan Bai
Phone 0518-82342973
Email xiaoyan.bai@hengrui.com
Status Not yet recruiting
Phase Phase 3
Start date June 2024
Completion date March 31, 2026
View Details
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT06012812 - A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis Phase 2
Completed NCT05549947 - Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis Phase 2
Recruiting NCT06136741 - A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis Phase 2
Recruiting NCT06099704 - Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent® for Moderate to Severe Atopic Dermatitis
Completed NCT03568162 - Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis Phase 2
Completed NCT00148746 - Standardized Time- and Score-oriented Treatment of Moderate and Severe Atopic Dermatitis N/A
Recruiting NCT05702268 - Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis Phase 2
Recruiting NCT05997927 - Efficacy and Safety Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis Phase 2
Not yet recruiting NCT05197023 - A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE SUBCUTANEOUS INJECTIONS OF SHR-1819 IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS Phase 1
Recruiting NCT06239311 - Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis. Phase 3
Terminated NCT01286220 - Dilute Bleach Baths in Pediatric Patients With Atopic Dermatitis N/A
Completed NCT02426359 - Safety and Efficacy Study of Q301 in Moderate to Severe Atopic Dermatitis Patients Phase 2